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UTILITY OF REPEAT SCREENING FOR ASYMPTOMATIC BACTERIURIA IN
PREGNANCY
Sara Whetstone, Stephen Thung, and Jessica Illuzzi. Department of Obstetrics,
Gynecology, and Reproductive Sciences, Yale University, School of Medicine, New
Haven, CT.
Asymptomatic bacteriuria (ASB) during pregnancy is associated with an increased risk of
developing pyelonephritis. The objectives of our study were to determine the incidence of ASB
throughout the first two trimesters of pregnancy and to compare the cost effectiveness of
performing repeat screening with a single screening strategy for ASB to prevent pyelonephritis.
In this prospective cohort study, 206 pregnant women at an urban academic obstetric clinic
provided urine for culture at monthly prenatal visits, and the incidence of ASB was calculated at
4 weeks intervals in the first and second trimesters. Descriptive statistics were calculated and
used as baseline estimates in the cost-effectiveness analysis. Decision and cost-effectiveness
analyses were performed. In the decision analysis, three strategies were compared: (1) no
screening; (2) screening for ASB once in the first trimester; and (3) screening for ASB once in the
first trimester and once between 18 and 22 weeks gestational age (GA).
9.71% of women were positive on initial screening culture for ASB. Among women with an
initial negative culture, the incidence rate of ASB was 0% at less than 14 weeks GA, 1.1%
between 14-18 weeks GA, 4.2% between 18-22 weeks GA, and 1.8% at greater than 22 weeks
GA. The proportion of women identified with ASB on initial culture did not differ statistically
from the proportion identified on repeat culture (McNemar’s test, p-value > 0.05). In the
decision analysis, a policy of routine screening in the first and second trimester (2 urine culture
strategy) was the dominant strategy compared to no screening and a single culture strategy.
The model was robust in the sensitivity analysis.
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INTRODUCTION
Understanding Asymptomatic Bacteriuria

Asymptomatic bacteriuria (ASB) or asymptomatic urinary tract infection signifies
bacteria in the urine in the absence of urinary tract specific symptoms. ASB occurs
across populations, especially amongst women, diabetic patients, elderly individuals,
and persons with spinal cord injury. The progression of ASB to more severe,
symptomatic disease has not been validated in many groups of patients, and
consequently screening for and treatment of ASB is not uniformly recommended. The
physiologic changes of pregnancy, however, put pregnant women at increased risk for
ascending infection. For this reason, the Infectious Disease Society of America (IDSA)
formally advocates for ASB screening and treatment among two groups of patients:
pregnant women and individuals undergoing urologic procedures.(1)
The microbiologic definition of ASB relies upon the urine culture, the threshold of
greater than 100,000 CFU/mL, and a confirmatory repeat culture. This triad has been
validated to distinguish true bacteriuria from contamination. The urine culture, despite
its expense, is considered the gold standard in the detection of ASB as other urine
screening tests perform poorly in comparison. Gram staining would be the most likely
alternative to urine culture given its high sensitivity of 90% and specificity of 88%;
however, it is a time consuming process and a relatively expensive method in an office
setting.(2, 3) Urinalysis and urine dipstick, while more rapid to perform, are considered
to be inadequate screening tools in pregnancy given their low sensitivities. Urinalysis
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for pyuria detects only 25-67% of samples identified as bacteriuric by culture, and urine
dipstick for leukocyte esterase or nitrite has a similar sensitivity in the range of 5073%.(2-6) Thus, the urine culture remains the test of choice as no other currently
available test has sufficiently high sensitivity and negative predictive value for ASB.
Prior to the 1950s there was no specific threshold in terms of bacterial number to
differentiate contamination from true bacteriuria. Kass determined that a bacterial
count of at least 100,000 CFU/mL in a voided specimen was confirmed in greater than
95% of subjects by a catherized specimen.(7, 8) Lower colony counts often were not
confirmed by catherization and represented contamination of the urine specimen by
vaginal and external flora during sample collection. In fact, if a sample had fewer than
100,000 CFU/mL, the probability was approximately 4% that the subsequent specimen
from the same patient would culture more than 100,000 CFU/mL.(7, 9) Interestingly in
practice today, many clinicians cite colony counts well below 100,000 CFU/mL as
justification for the use of antibiotics in pregnancy given the risks of untreated ASB. (see
Section “Asymptomatic Bacteriuria in Pregnancy”).
The definition of true ASB as defined by IDSA requires at least two consecutive voided
urine specimens with greater than 100,000 CFU/mL of the same bacterial strain.(1) Kass
demonstrated that bacteriuria was confirmed in only 80% of women if only one voided
urine culture was used to diagnose ASB but was confirmed in greater than 95% of
women if two previous specimens showed bacteriuria.(8, 10) In practice today, a
single-voided midstream urine with greater than 100,000 CFU/mL is accepted as an
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adequate alternative definition of ASB.(11) We suspect that practitioners find obtaining
repeat specimens from their patients impractical as prenatal visits occur only once a
month in early pregnancy.
Based upon the aforementioned definition of ASB, its prevalence amongst pregnant
women has been reported to range from two to ten percent.(12, 13) Similar prevalence
rates are reported in non-pregnant women, and accordingly pregnancy is not believed
to be a risk factor for its development.(12) The microbiology of ASB in pregnancy
reflects the organisms isolated from non-pregnant bacteriuric women. Escherichia coli
is the most common pathogen with an estimated prevalence of 65 to 80%, followed by
other gram-negative organisms such as Proteus mirabilis, Klebsiella pneumoniae and
Enterobacter.(11, 14) Gram-positive bacteria like Enterococcus, Streptococcus
agalactiae, and Staphylococcus saprophyticus have been identified as causing
bacteriuria, particularly in the last trimester, and there is increasing recognition of
fastidious organisms, such as Ureaplasma urealyticum, as urinary pathogens.(15-17)
Increased prevalence of ASB is associated with multiparity, multiple sexual partners,
increasing age, and low socio-economic status.(18) Women with diabetes mellitus and
sickle cell disease or trait have also been identified as individuals who have higher rates
of bacteriuria due to alterations in genitourinary tract function. Individuals with chronic
diseases that impair voiding or that involve long-term indwelling catheters have even
higher rates of ASB.
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Asymptomatic Bacteriuria in Pregnancy
Women are anatomically predisposed to bacterial colonization of the bladder– the
external third of the urethra is colonized by vaginal flora and sexual intercourse
increases the risk of urinary infection. Changes in the genitourinary tract during
pregnancy predispose women to pyelonephritis; over 80% of pyelonephritis cases occur
in the second and third trimesters, a period of time when physiologic adaptations of
pregnancy promote greater urinary stasis and bacterial proliferation.(19) The most
notable of these changes is the dilatation of the collecting system. Progesterone
induces smooth muscle relaxation, leading to decreased ureteral peristalsis and
tone.(20) Additionally, the enlarging uterus extends beyond the pelvis in mid-pregnancy
to compress the ureters at the pelvic brim; interestingly, the right ureter, the side where
pyelonephritis more frequently develops, experiences greater dilation due to
dextrorotation of the uterus, while the left ureter is cushioned by the sigmoid colon.(21)
The hypertrophy of Waldeyer’s sheath, the longitudinal muscle at the lower ureter, may
contribute to further dilatation proximally by functionally compressing the lower
ureter.(20) As a result of anatomic, physiologic, and hormonal changes, the upper
collecting system can accommodate 200 to 300 mL of urine and becomes a potential
reservoir for infection.(20)
Other changes may also increase pregnant women’s susceptibility to urinary tract
infections. Like the ureters, the bladder experiences a progesterone-induced decrease
in tone and subsequent increase in capacity; the expanding uterus, however,
simultaneously displaces the bladder superiorly and anteriorly, causing it to flatten out
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and decrease its capacity. Despite conflicting results about the bladder’s capacity in
pregnancy, some authors speculate an anatomic change occurs that renders the bladder
more susceptible to infection; its flaccidity may also contribute to vesicoureteral reflux
and increase the likelihood of ascending infection.(22, 23)
Hormonal factors of pregnancy may additionally alter susceptibility to infection. In
experimental settings, rats who received diethylstilbestrol were more likely to
experience renal parenchymal infection with E coli, and urine from women who used
oral contraception had an increased rate of in vitro bacterial growth.(24, 25) In
addition, the glucosuria and aminoaciduria of pregnancy, resulting from decreased
fractional absorption in the kidney, facilitate bacterial proliferation in urine, an already
excellent growth medium. The net effect of these changes is to increase the likelihood
of a symptomatic urinary tract infection to develop during pregnancy.
Bacteriuria has been shown to be the most significant factor associated with
development of acute pyelonephritis in pregnancy.(9, 10) The risk of pyelonephritis
ranges from 20-40% among pregnant women with untreated ASB.(10) (12) Therefore,
women with ASB detected in pregnancy have a 20-30-fold risk of developing acute
pyelonephritis in comparison to pregnant women without bacteriuria.(14, 26, 27) The
relationship between bacteriuria and acute pyelonephritis is substantiated by the fact
that the bacterial species cultured from women with acute pyelonephritis mirror those
cultured from women with bacteriuria. E coli is the most common pathogen amongst
women with acute pyelonephritis, accounting for greater than 70% of cases.(11, 19)
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Today, in the era of screening and treatment of ASB, the overall incidence of
pyelonephritis in pregnancy is relatively low, at one to two percent.(21) Nonetheless,
pyelonephritis continues to be the most common serious medical complication of
pregnancy and genitourinary complications account for approximately 10% of antenatal
admissions to the hospital.(28) Acute pyelonephritis in pregnancy also results in
significant maternal and fetal morbidity. At the time of diagnosis, approximately 20% of
women have concurrent bacteremia, and a similar percentage of women experience
multi-organ system dysfunction.(19, 29, 30) It is believed that endothelial activation
and subsequent capillary fluid extravasation lead to alterations in blood pressure, renal
function, and gas exchange.(21) These vascular changes cause intravascular depletion,
and hypotension is fairly common(21) Diminished renal function, albeit often transient,
occurs in 5% of women, although in the past, 10-20% of women were reported to
experience kidney injury.(19, 30) Twenty percent of pregnant women with
pyelonephritis develop anemia during their infection, attributed to endotoxinstimulated hemolysis.(31) Those women who unfortunately develop severe sepsis are
at risk for activation of coagulation pathways. The most concerning complication is the
development of acute pulmonary injury from suspected endotoxin-mediated damage to
alveolar capillary membranes. The resultant respiratory insufficiency, seen in 2-8% of
women, ranges in severity from an increased oxygen requirement to severe acute
respiratory distress syndrome requiring intubation and mechanical ventilation.(32, 33)
Urosepsis, or proliferation of the uropathogen within the bloodstream, is the leading
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cause of septic shock during pregnancy, and one study reported that nearly 10% of
women with pyelonephritis required admission to the obstetric intensive care unit.(19)
Prior to the 1940’s and before the use of antibiotics, acute pyelonephritis was clearly
associated with a 20-50% incidence of preterm birth. (27, 34, 35) The mechanisms for
preterm labor resulting from pyelonephritis have not been completely elucidated but
are presumed to be related to endotoxin-stimulated uterine activity or bacterial
production of phospholipase A2. A recent large cohort study (2005) found that preterm
birth occurred in only 5% of women with acute pyelonephritis who received antibiotic
therapy, a rate comparable to that of the general obstetric population today.(19) The
association between bacteriuria and preterm birth is more controversial. Kass initially
reported an increased risk of preterm birth in women with persistent bacteriuria, a risk
that could be modified by the use of antibiotics throughout gestation.(9, 10)
Subsequent studies of various designs showed conflicting results, with most failing to
demonstrate a relationship between preterm birth and ASB. Those studies that
revealed an excess rate of preterm delivery with bacteriuria were often statistically
underpowered or did not show that treatment altered the rate of prematurity.(12) A
meta-analysis of 17 cohort studies found a strong association between ASB and low
birth weight/preterm delivery and additionally demonstrated that antibiotic treatment
reduced the rate of low birth weight.(36) Critiques of the meta-analysis cite poor
methodological quality of the studies included in the analysis, inability to define a
mechanism in which bacteriuria causes preterm labor, and failure to control for
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infections outside the urinary tract, particularly those in the cervix and vagina, that may
respond to antibiotics and that have been linked to prematurity.(12, 35) If bacteriuria
does contribute to preterm delivery, as Whalley stated, it accounts for a very small
proportion and ASB treatment will minimally affect the rate of preterm birth.(12)
Screening and Treatment of Asymptomatic Bacteriuria in Pregnancy
There is convincing evidence that antibiotic treatment of ASB is effective in preventing
the well-established adverse maternal outcomes, such as pyelonephritis, sepsis, and
ARDS. A systematic review of 14 studies comparing antibiotic treatment with no
treatment or placebo found that antibiotic treatment was effective in clearing ASB (OR
0.07, 95% CI 0.05-0.10) and was associated with a reduced incidence of pyelonephritis
(OR 0.24, 95% CI 0.19-0.32).(35) In the literature, there is no single antibiotic that is
optimal in the treatment of ASB, and no study has had the power to determine the
optimal duration of therapy; therefore, current recommendations encourage empiric
treatment of ASB. Even with antibiotic treatment, it should be noted that the
recurrence rate of ASB is reported to be 20-30%.(12)
Based on the evidence, screening for ASB in pregnancy has been incorporated into
prenatal care in most developed countries for decades. Trials have repeatedly shown
that screening and treatment of ASB has substantially decreased the incidence of
pyelonephritis in pregnancy.(35) Implementation of such programs in Spain resulted in
a decrease in incidence of pyelonephritis from 1.8% to 0.6% and in Turkey from 2.1% to
0.5%.(37, 38) In the United States, the incidence of pyelonephritis has declined from 3-
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4% in the 1970s to 1-2% with universal screening.(39, 40) When compared with a
policy of no screening, screening for and treatment of ASB in pregnancy is regarded to
be cost-beneficial.(41) Another study showed a single screening culture in first
trimester to be cost-effective if the prevalence of bacteriuria is greater than 2% and the
risk of pyelonephritis in bacteriuric women is greater than 13%.(42)
Accordingly, the United States Preventive Services Task Force (USPSTF), American
College of Obstetricians and Gynecologists (ACOG), American Academy of Pediatrics
(AAP), American Academy of Family Physicians (AAFP), and IDSA recommend screening
for ASB in early pregnancy.(43, 44) Some of these national organizations even explicitly
state that screening should occur at 12 to 16 weeks gestational age (GA) or at the first
prenatal visit if after that time. The timing of screening is based on reports that the
majority of bacteriuria was present by the second month of gestation.(10) Moreover,
initial published studies reported that pyelonephritis occurred only amongst women
identified with ASB at the initial visit and thus it followed that women should be
screened when they first presented for prenatal care.(8, 10) Later studies contradicted
these earlier reports and showed that approximately one to two percent of pregnant
women with negative initial cultures develop pyelonephritis.(1, 14, 26, 27) This latter
figure has two interesting implications, the first being that it is likely that a proportion of
women develop bacteriuria later over the course of pregnancy despite an initial
negative culture. This bacteriuria is most likely unrecognized and untreated leading in
some cases to pyelonephritis. The second is that the absolute number of women who
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initially test negative but go on to develop pyelonephritis (1-2%) is what would be
expected if 2-10% subsequently developed ASB and were not treated (20-40% of 2-10%
or 0.4-4%). This should raise concern that the rate of ASB may be similar in first
trimester and second trimesters. An example will help to illustrate this second point
(see Table 1). In a cohort of 1000 pregnant women with a 6% rate of ASB at initial
culture (60 women), twelve women will develop pyelonephritis if untreated, assuming a
20% risk of pyelonephritis. Of the 940 women with initial negative cultures,
approximately fourteen women will develop pyelonephritis, given a 1.5% incidence rate
of pyelonephritis over the course of pregnancy. Accordingly, current screening
procedures have been cited to only detect 40-70% of women who develop
pyelonephritis.(45-47)
Table 1. Percentage of women predicted to develop pyelonephritis identified by
current screening methods using published estimate ranges in a cohort of 1000 (12, 41,
44)
Low Estimate
2%

Middle Estimate
6%

High Estimate
10%

Risk of pyelonephritis

20%

20%

20%

Incidence of pyelonephritis among
initial culture negative women

1%

1.50%

2%

Number of women with positive initial
culture who develop pyelonephritis
(assuming no treatment)A

4

12

20

Number of women with negative initial
culture who develop pyelonephritisB

9.8

14.1

18

29.0%

46.0 %

52.6%

Prevalence of ASB at initial culture

Percentage of women who develop
pyelonephritis who are detected by
screening at initial visitC

A
Number of women with positive initial culture who develop pyelonephritis (assuming no treatment) = population of women (N) x
rate of ASB x risk of pyelonephritis if no treatment
B
Number of women with negative initial culture who develop pyelonephritis = (N - number of women with ASB at first culture) x
1%
C
Percentage of women who develop pyelonephritis who are detected by screening at initial visit = Number of women with positive
initial culture who develop pyelonephritis (assuming no treatment)/Total number of women who develop pyelonephritis
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Although screening programs have been commended for their successes, there are gaps
in the published literature which limit current recommendations. The IDSA and USPSTF,
among others, have reported that no study has fully addressed the optimal timing for
the initial urine culture.(35, 44, 48) A Swedish study reported that screening at 16
weeks would be the optimal time to maximize detection of ASB as well as the number of
bacteriuria-free weeks in pregnancy.(49) In the United States, there has been no
systematic effort to study the ideal time for initial ASB testing despite the fact that
nearly 30 to 60% of women who develop symptomatic urinary tract infection in
pregnancy are not identified by initial screening measures. The benefit from additional
screening in pregnancy is unknown. In fact, Nicolle et al. write, “It has not been
evaluated whether a second screening culture obtained in later pregnancy would
further reduce the risk of pyelonephritis and its complications, and remain costeffective.”(44)
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STATEMENT OF PURPOSE
Given the remaining questions about ASB screening, the aims of the study are to
calculate the incidence rate of ASB at various times in pregnancy using a prospective
cohort of women and to evaluate the cost-effectiveness of performing repeat cultures
for ASB in pregnancy. The ultimate goal of the research is to inform cost-effective
evidence-based guidelines for the timing of asymptomatic bacteriuria screening in order
to optimally reduce the incidence of pyelonephritis and its associated maternal
morbidity. It is our hypothesis that a greater proportion of women will develop ASB
after an initial negative culture than previously reported in the literature, and thus
repeat screening will be cost-effective given the high costs of managing acute
pyelonephritis in pregnancy.
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METHODS
Overview
The study design consisted of two components to determine the cost-effectiveness of
repeat screening for ASB in pregnancy. As the literature lacked detailed data on the
incidence of ASB throughout pregnancy, the first component involved longitudinal ASB
screening of a cohort of low risk pregnant women in order to calculate the incidence
rate of ASB at various gestational ages. The second component, a cost-effectiveness
analysis, used the incidence rates generated as probability estimates and evaluated the
strategy of repeat screening for ASB in pregnancy. In both components, the urine
culture was used as the screening tool of choice for ASB.

Screening
Beginning September 2007, women with a documented pregnancy who presented for
prenatal care at the Women’s Center at Yale-New Haven Hospital were invited to
participate in the study. The Women’s Center serves as a site of care for low risk
obstetric patients; women with significant co-morbidites are referred to another facility
for care by maternal-fetal medicine specialists. The study protocol was approved by the
Human Investigation Committee at Yale University, and informed written consent was
obtained for all subject participants. Exclusion criteria were gestational age beyond 28
weeks, insulin-requiring diabetes mellitus, sickle cell disease, chronic kidney disease,
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and an inability to undergo the informed consent process in either English or Spanish.
Women who were unable to provide at least two urine cultures, i.e. those who
presented late in the second trimester, were also excluded from the study. Study
enrollment ended in April 2008, and ASB screening finished in August 2008.
As per ACOG guidelines, an initial screening urine culture was obtained at the first
prenatal visit. All women were instructed how to perform a midstream clean catch. At
subsequent monthly prenatal visits, study participants were asked to provide clean
catch urine for culture. Screening continued until 28 weeks gestational age or until
women developed true ASB, symptomatic urinary tract infection (UTI), or acute
pyelonephritis; these scenarios all result in antibiotic treatment and have the potential
to confound further screening cultures. It was decided not to screen in the late third
trimester as the most likely time for a second screening culture would be in the second
or early third trimester as the vast majority of cases of pyelonephritis develop in these
trimesters. Gestational age was calculated using a woman’s last menstrual period
(LMP) and verified by first or second trimester dating ultrasound; if there was inaccuracy
in dating by LMP, dating was changed to reflect that estimated by ultrasound.
All urine cultures were sent to the Yale-New Haven Hospital microbiology laboratory for
processing and analysis. Cultures obtained for the study were handled identically as
those urine cultures collected for routine patient care; results were reported to
clinicians in the usual fashion. Outcome measures included the incidence of ASB in four
week intervals as well as the incidence of pyelonephritis. The incidence of ASB was
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calculated based on the result of one urine culture with greater than 100,000 CFU/mL of
at least one identified bacterial specimen, excluding lactobacillus. The broad inclusion
of many bacterial species was based on the description of microbiology of ASB by the
IDSA; accordingly, bacterial species included within our definition were Escherichia coli,
Klebsiella pneumonia, Proteus mirabilis, other Enterobacteriaceae, coagulative-negative
staphylococci, Enterococcus, group B streptococci, Staphylococcus aureus, Streptococcus
viridians, and Garnerella vaginalis.(1) The incidence of pyelonephritis was calculated by
the number of women diagnosed with acute pyelonephritis in pregnancy amongst our
study population. It should be noted that the diagnosis of pyelonephritis was
determined by the participant’s clinical care providers and validated based on
documentation of two or more clinical findings (fever, flank pain, and costovertebral
angle tenderness) in the medical record. Secondary outcome measures were the rate of
pre-term birth (less than 37 weeks GA) and low birth weight (less than 2,500 grams).
Given the clear evidence that treatment for asymptomatic bacteriuria reduces the risk
of pyelonephritis, all women found to have ASB were offered antibiotics and requested
to provide a urine specimen for test of cure. Decisions regarding the need for repeat
urine cultures, further screening for bacteriuria, and need for antibiotic suppression
were delegated to the participants’ clinicians. Treatment of positive urine cultures that
did not meet the criteria for ASB were deemed the responsibility of the patients’
clinicians; however, prior to the study’s commencement, all clinicians were provided
with education about evidence-based criteria for ASB and encouraged to seek repeat
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cultures for women with positive cultures that did not meet the 100,000 CFU/mL
threshold. Women who received antimicrobial agents during the study period were
encouraged to provide urine for test of cure but they did not continue on the monthly
screening regimen as antibiotics most likely altered the flora of their genitourinary tract.
It should also be noted that the management of symptomatic UTI was determined by
the participant’s primary provider. A symptomatic UTI was defined as greater than
>100,000 CFU on urine culture in the presence of common symptoms (i.e. dysuria,
frequency, urgency, lower abdominal cramping). Subjects with this diagnosis were not
counted as cases of ASB.
Patient characteristics such as gravidity, parity, age, history of diabetes mellitus, sickle
cell trait, and history of previous urinary tract infections -- all factors known to influence
the prevalence of ASB -- were extracted from medical records.
Descriptive statistics, incidence rates, and confidence intervals were calculated using
SAS 9.1 and EXCEL. Likewise, women with and without ASB were compared.

Decision Analysis
Using a decision tree model, three strategies were compared to evaluate the costeffectiveness of ASB screening in the prevention of pyelonephritis. These strategies
included (1) a policy of no screening, (2) a policy of screening for ASB once in the first
trimester, and (3) a policy of screening for ASB once in the first trimester and once
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between 18 and 22 weeks gestational age. In the first strategy, no routine urine
cultures were performed and women who had asymptomatic bacteriuria were left
untreated. For the sake of the model, there were two opportunities for ASB, once in the
first trimester and once in the second trimester. Given that unscreened women were
asymptomatic, we assumed they were untreated and at high risk for pyelonephritis and
ARDS. In the second strategy, the current standard of care, women who entered
prenatal care in the first trimester received one routine urine culture. Similar to the first
strategy, there were two opportunities for ASB and progression to pyelonephritis.
Asymptomatic bacteriuria in the first trimester was treated with antibiotics and a test of
cure was performed. The risk of pyelonephritis due to first trimester ASB was
significantly reduced by identification and treatment. A repeat screening urine culture
was not performed in the 2nd trimester leaving an elevated risk of pyelonephritis similar
to the first strategy. The third strategy, our test strategy, allowed for routine urine
cultures in the first and second trimester. If ASB was identified in either case, it was
treated and the risk of progressing to pyelonephritis was low. In all cases, women with
pyelonephritis were at risk of progressing to ARDS. Furthermore, all women diagnosed
with pyelonephritis received antibiotic treatment and chronic antibiotic suppression
therapy for the remainder of the pregnancy.
Figure 1 displays the schematic decision tree used in this analysis. (For actual decision
trees, see Appendix A-C.)
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Figure 1. Schematic decision tree model comparing no screening, screening in the first
trimester, and screening in the first and second trimester for asymptomatic bacteriuria
in pregnancy.

Probability estimates
The baseline probabilities were obtained after a thorough review of English medical
literature and are summarized in Table 2. We estimated the average prevalence of ASB
among pregnant women in the first trimester to be 6%, a figure that represents the
median value of previous prevalence estimates reported between 2-10%.(12, 41, 42)
The risk of pyelonephritis among untreated bacteriuric women was estimated at 21%;
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this risk was derived from a meta-analysis of 14 studies that involved 2302 women and
reported the rate of progression from untreated ASB to pyelonephritis. The range of
estimates for progression to pyelonephritis in this study was broad, from 2.5% to
36%.(35) The risk of pyelonephritis among women who were initially ASB-negative has
been quoted in the literature to be 1-2%, and in the decision analysis we estimated the
risk of progression to pyelonephritis among initially culture-negative women to be
1%.(12, 13)
For the purposes of this analysis, we assumed women enter prenatal care in the first
trimester and that women identified with ASB are treated. Antibiotic efficacy is
reported to be 80-90% in clearing bacteriuria; thus, we made an assumption that 20% of
women will have a positive follow-up urine culture and require suppressive therapy.(11,
50) Women with treated ASB have been reported to have an increased risk of
pyelonephritis (0-17%), and thus like Rouse et al, we estimated their risk of progression
to pyelonephritis to be 3% for both women requiring and not requiring antibiotic
suppression.(35, 41)
We deemed the inclusion of ARDS important as its risk of development provides, in part,
the rationale for inpatient management of pregnant women with acute pyelonephritis.
Approximately 2-8% of cases of acute pyelonephritis in pregnancy are complicated by
respiratory insufficiency, and a recent prospective longitudinal study of women
hospitalized for pyelonephritis in pregnancy reported that 7% (95% CI 5-10%) of women
developed respiratory insufficiency.(19, 32, 33) We used the estimate of 5% of women
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with acute antenatal pyelonephritis develop ARDS in pregnancy and require admission
to ICU.(19)
For the policy of screening twice for ASB, we utilized data from our prospective cohort
and estimated the prevalence of ASB at 18-22 weeks GA to be 3.4%. The calculated
incidence rate of ASB at 18-22 weeks was 4.21% (see Results section); however, we
assumed that 80% of our incidence rate represented true bacteriuria as only one voided
urine culture was used to define ASB. Additionally, we estimated that the rate of ASB
positivity on second trimester screen amongst women found to have ASB on the first
trimester screen to be 25%. The recurrence rate of bacteriuria in pregnancy is reported
to be between 20 and 30%, and we used the median value for our baseline
estimate.(14, 46, 50) Our prospective cohort study was not powered to detect the
incidence rate of pyelonephritis among women with two negative cultures. However,
3.0% of our study population developed ASB after two negative cultures, corresponding
to a rate of 2.4% given the 80% probability of true bacteriuria with the use of a single
culture. From this statistic, we calculated a risk of pyelonephritis among women with
negative first and second trimester ASB screening. We predicted that women with two
negative cultures who subsequently developed ASB would not be detected by the first
and second trimester screening and thus would have a 21% risk of pyelonephritis.
Therefore, we estimated that women with a negative first and second trimester screen
had a 0.50% risk of progression to acute pyelonephritis.
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Table 2. Baseline Estimates for Cost-Effectiveness Analysis
Baseline
Estimate

Range

st

6

2.0 - 10.0

12, 41, 42

nd

3.4

0.9 – 8.6

n/a

Untreated ASB (%)

21

2.5 - 36

35

Treated ASB (%)

3

0 - 17

After one negative culture (%)

1

1.0 - 2.0

After two negative cultures (%)

0.50

0-2

25

20 - 30

14, 46, 50

20

10 - 20

11, 50

5

2-8

Variable

Reference

ASB Prevalence
Prevalence of ASB at 1 TM (%)
Prevalence of ASB at 2 TM (%)
ASB progression to pyelonephritis
35, 41
1, 12, 13, 41
n/a

Risk of recurrence
ASB in 2nd TM after ASB in 1st TM (%)
st

Risk of ASB after treatment in 1 TM
ASB in 2nd TM after treatment (%)
Risk of ARDS
ARDS with acute pyelonephritis (%)

19, 32, 33

Cost Estimates
All costs are presented in 2008 US dollars. For the analysis, published non-wholesale
prices from www.drugstore.com were utilized for all medication costs, and other costs
were drawn from the published literature (Table 3). The cost of a 7-day course of
antibiotics was derived from averaging the price of 3 different generic medication
regimens (cephalexin, nitrofurantoin, and sulfamethoxazole-trimethoprim), as there is
no single optimal antibiotic regimen for the treatment of ASB. The cost of an antibiotic
regimen was estimated to be $9.30.(51) Approximately 10% of women treated for ASB
are reported to develop vaginal candidiasis; the cost of a generic antifungal medication
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for 1 week was $12.(51, 52) Thus, the cost of antibiotic treatment for ASB was
estimated to be $10.50 [$9.30 + (10% x $12)]. Those women with pyelonephritis as well
as women with repeatedly positive cultures were assumed to require antibiotic
suppression therapy for the duration of the pregnancy. A common antibiotic regimen
for suppression, 100 mg nitrofurantoin each night, was found to have a cost of $160 for
a 20 week course or $8 per week.(51)
Given that the treatment for ASB is empiric, only the cost of a urine culture without
antibiotic sensitivities was needed; however, with increasing antibiotic resistance, many
clinicians obtain antibiotic sensitivity at time of initial culture. Urine culture cost was
determined from 2008 Medicare data and encompassed the cost of urine culture,
colony count, and antibiotic sensitivity.(53) As mentioned earlier, pyelonephritis in
pregnancy is often treated on an inpatient basis. The costs to the patient and her family
extend beyond the charges for hospitalization and treatment and include lost income
and childcare; however, this analysis utilized only direct hospital costs. In analysis of
costs associated with acute pyelonephritis, Brown et al used an estimate of $6580 and
$4312 for the direct costs associated with inpatient treatment of pyelonephritis with
and without bacteremia, respectively.(54) Taking into consideration that 20% of
pregnant women with acute pyelonephritis are bacteremic at time of presentation, the
cost estimate was $4698 [80% x $4312 + 20% x $6580] and was adjusted using the
medical care component of the Consumer Price Index to reflect 2008 US dollars.(19, 41)
Health care costs for ARDS are considerable because patients are almost exclusively
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managed in an expensive ICU setting, with mean costs ranging from $48,000 to $73,000;
we used the conservative estimate of $48,000 for our analysis.(55-57) We chose the
lower estimate for our model as we assumed that most pregnant women are younger
and healthier than many other patients admitted to the ICU with ARDS, thus most likely
will require less care in comparison.

Table 3. Cost Estimates for Decision Tree Model

Variable

Baseline
Estimate ($)

Range ($)

11.79

10 - 55

10.50

7.80 – 57.60

51

160

120-336

51

5795

3562-8117

19, 41

48,000

48,000 – 73,000

55 - 57

Reference

Screening
Urine culture

53

Antibiotic Therapy
7-day course
Suppression therapy
Treatment of Acute Pyelonephritis
Inpatient hospital costs
Management of ARDS
Intensive care unit costs

Analysis
A baseline decision and cost analysis was performed using TreeAge Pro 2008 (TreeAge
Software, Williamstown, MA). Sensitivity analyses were subsequently done in
recognition that our baseline estimates may not be applicable to all populations. The
decision analysis model was used to estimate the number of cases of pyelonephritis and
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ARDS that would occur with no screening, a first trimester screening culture only, and
both a first and second trimester screening. Calculated costs of each strategy
encompassed ASB screening and treatment costs as well as costs of inpatient treatment
of acute pyelonephritis and ARDS. Costs of the one culture strategy and two culture
strategy were compared to that of the no screening strategy. Incremental savings of
1st/2nd trimester urine cultures were calculated by subtracting expected costs of the
repeat culture strategy from those of the single culture strategy.
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RESULTS
Prospective Cohort Study
Of the 250 women invited to participate in the study, 206 women comprised the study
population, representing an acceptance rate of 82.4%. Of those, over 90% provided at
least two urine cultures during the screening period, and over 70% provided at least
three ASB screening cultures. Figure 2 shows detailed information on enrollment and
retention.
Figure 2. Overview of Patient Enrollment and Retention

250 women invited to participate
44 women ineligible or did
not consent to participate

206 women eligible and
consented to participation
(82.4% acceptance rate)

Beyond 28 weeks GA (n=5)
Language barrier (n=8)
Refused to participate
(n=31)

14 women provided 1 urine culture
for ASB screening

192 women provided at least
2 urine cultures for ASB
screening
(93.2% retention rate)

Lost to follow-up (n=5)
Spontaneous abortions (n=2)
Patient refusal (n=2)
Missed appointments (n=4)
Transferred care to another facility
(n=1)
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The mean age of participants was 24.3 years (SD 5.3). Forty-two percent were AfricanAmerican, and 48.5 percent were Hispanic. Most women were multiparous (median
gravidity and parity of 2 and 1, respectively). Only 7.8% of the study cohort possessed
one or more known risk factors for ASB. (i.e. diabetes mellitus, sickle cell trait, history of
pyelonephritis). The vast majority of subjects carried singleton gestations; there was
one twin gestation. During the study period, there were a total of 27 cases of ASB.
There were no significant differences in demographic and clinical characteristics
between women with and without ASB, with the exception that women with ASB were
more likely to have a documented history of urinary tract infection (Table 4).

Table 4. Selected demographic and clinical characteristics of women with ASB compared
with women without ASBD
Women positive for
ASB (N=27)

Women negative for
ASB (N=179)

p-value

22.6(5.4)

23.4(5.2)

0.587

Median Gravidity

3 (2-4)

2 (2-3)

0.205

Median Parity

1 (0-2)

1 (0-2)

0.772

Mean Age

0.596

Race/Ethnicity

D

African-American

10 (37.0)

74 (42.8)

Caucasian

14 (51.9)

84 (48.6)

Hispanic

2 (7.4)

13 (7.5)

Other
Patients with presence of at least
one known risk factor of ASB

1 (3.7)

2 (1.2)

5 (18.5)

12 (6.7)

0.053

Diabetes mellitus

1 (3.7)

0 (0)

0.52

History of Pyelonephritis

1 (3.7)

5 (2.8)

0.136

Immunosuppression

1 (3.7)

0 (0)

0.52

Sickle cell trait
Documented history of UTI

2 (7.4)

3 (1.7)

0.523

7 (25.9)

17 (9.8)

0.026

Current Smoking

5 (18.5)

18 (10.4)

0.208

Continuous variables expressed as mean + SD. Comparisons made using Student t test.
Categorical variables expressed as number of patients(%). Comparisons made using Fisher’s exact test.
Ordinal variables expressed as median (interquartile range). Comparisons made using Wilcoxon test.
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The mean gestational age at ASB detection was 15.0 (SD 5.5) weeks. The prevalence
rate of ASB was 8.93% at less than 10 weeks GA, 5.6% between 10-14 weeks GA, 4.1%
between 14-18 weeks GA, 6.60% between 18-22 weeks GA, and 2.61% at greater than
21 weeks GA. Among women who developed ASB, 18.5% had one known risk factor
compared to 6.7% of women who did not develop ASB during the study period, a
difference that was not statistically significant (See Table 4). Moreover, women with
known risk factors for ASB were not more likely to develop ASB throughout gestation in
comparison to women without such risk factors (see Table 5).

Table 5. Number of women with and without known risk factors who developed ASB by
gestational ageE
Women with risk factors
(N=16)

Women without risk
factors (N=190)

14-18 wks

1
1
0

5
5
5

18-22 wks

2

6

Gestational age window
<10 wks
10-14 wks

p-value
0.918

0
2
>22 wks
Risk factors include sickle cell trait, non-insulin requiring diabetes mellitus, immunosuppression, and
history of pyelonephritis

E

As shown in Table 6, the predominant organism was Escherichia coli, accounting for 41%
of all cases of ASB. The next most common uropathogen was group B Streptococcus and
other gram positive organisms. Notably amongst all ASB bacterial isolates with
documented sensitivities, 66.7% were resistant to at least one antibiotic agent, and
ampicillin resistance in E coli was found to be 36.4%.
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Table 6. Frequency of uropathogens in ASB-documented urine culturesF
Urine Culture Results

F

Escherichia coli

11 (41)

Klebsiella-Enterobacter group

4 (15)

Proteus species

2 (7)

Enterococcus species

3 (11)

Group B streptococcus and other
gram positive organisms

7 (26)

Total
Data reported as number of patients(%).

27 (100)

Of note, there were additional positive cultures with colony counts below 100,000 that
did not meet the study’s definition of ASB. The prevalence rates of any positive urine
culture are reported in Table 7; like the trend seen amongst all cases of ASB, the
observed prevalence rates peak in the gestational age windows of 10-14 weeks and 1822 weeks.

Table 7. Prevalence of ASB by gestational age for all cases of ASB and among women
who were initial culture-negative and prevalence of any positive urine culture by
gestational age.G
Gestational age window

All cases of true
ASB

Any positive
urine culture

True ASB among initial
culture-negative women

> 10 to 14 weeks GA

5.6% (2.3- 11.5%)

10.4% (5.5- 17.8%)

0% (0 – 16.8%)

>14 weeks to 18 weeks GA

4.1% (1.3 – 9.6%)

6.6% (2.8 – 12.9%)

1.1% (0 - 6.3%)

>18 weeks to 22 weeks GA

6.6% (2.7 - 13.6%)

11.3% (5.8 - 19.8%)

4.2% (1.1 – 10.8%)

> 22 weeks GA

2.6% (0.5 - 7.6%)

2.6% (0.5 – 7.6%)

1.8% (0.2 – 6.4%)

G

Data shown as estimates (95% Confidence Interval)

The prevalence of ASB at initial culture was 9.71%, and the mean gestational age at the
time of this culture was 12 weeks (SD 3.5). Given the use of one culture to define ASB,
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and the results of Kass et al. suggesting that 80% of cultures growing 100,000 colonies
are confirmed positive upon repeat culture, we calculated an adjusted prevalence rate
to be 7.77%.(8, 10)

Figure 3. Analysis using McNemar statistic for
the number of women identified with ASB on
initial culture and on subsequent culture

On Repeat Culture
On Initial
Culture

ASB -

ASB +

ASB -

165

8

173

ASB +

15

4

19

180

12

The proportion of women identified with ASB on initial culture did not differ statistically
from the proportion identified by later cultures during gestation (McNemar’s test, pvalue > 0.05; Figure 3). For those women who did not have bacteriuria on initial
culture, the incidence rate of ASB in the remainder of the study was 4.34% (95% CI 1.75
– 8.96%). Among women with an initial negative urine culture, the incidence rate of
ASB was 0% up to 14 weeks GA (95% CI 0.0– 16.8%), 1.1% between 14 and 18 weeks GA
(95% CI 0.0 – 6.3%), 4.2% between 18 and 22 weeks GA (95% CI 1.1– 10.8%), and 1.8%
beyond 22 weeks GA (95% CI 0.2 – 6.4%)(Figure 4). The mean gestational age of ASB
detection was 20.5 (SD 2.9) weeks for initially culture-negative women. Interestingly,
among all women who had at least 2 documented negative urine cultures (N= 134), only
4 developed ASB, a rate of ASB of 3.00% (95% CI 0.81 – 7.64 %).
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Figure 4. Incidence rate of ASB among women with initial negative culture

Of note, there were 11 documented symptomatic urinary tract infections, 8 of which
were uncomplicated cases of cystitis. E coli was the most common organism
responsible for symptomatic UTIs, accounting for 63.6% of such infections. Three cases
of acute pyelonephritis were diagnosed amongst the study population, resulting in an
incidence rate of 1.46% or 14.6 per 1000 pregnancies. All episodes of pyelonephritis
occurred in the second trimester and at average gestational age of 19.8 weeks GA
(SD=0.3). Diagnosis of pyelonephritis was based on clinical findings of fever
(temperature>38°C) (n=2), flank pain (n=3), and costovertebral angle tenderness (n =2).
Analysis of urine revealed bacteriuria with > 100,000 CFU/mL in 66.7% (n=2) of cases
and pyuria (>5 leukocytes per HPF) in 100% (n=3) of cases. All women with symptomatic
urinary tract infections received antibiotic therapy. No woman required admission to
the intensive care unit while receiving inpatient treatment for pyelonephritis. Of note,
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one of the three women diagnosed with acute pyelonephritis had previous successful
treatment for uncomplicated cystitis; another woman, with known poorly controlled
HIV, was diagnosed with asymptomatic bacteriuria but never received treatment, and
the third woman did not have any positive urine cultures throughout gestation,
including at the time of diagnosis for pyelonephritis.
Amongst our study population, there were 21 cases of preterm birth, comprising 11.4%
of all documented births. Of these preterm deliveries, 42.9% resulted from
spontaneously preterm birth, and the remainder resulted from obstetric intervention
for maternal or fetal indications. The rate of low birth weight, infants less 2500 grams,
was 4.4%; however if gestational age is considered, the rate of small for gestational age
infants was only 1.65%. Amongst women with ASB, there were 4 cases of preterm
delivery, of which only one was the result of spontaneous preterm labor, and there
were no small-for-gestational age infants. The rate of preterm delivery or low birth
weight amongst women with bacteriuria did not differ significantly from the rate
amongst non-bacteriuric women. (Fisher’s exact test p=0.287 and p=1.0, respectively)
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Cost-Effectiveness Analysis
Table 8 shows the costs of each screening strategy, and notably total direct costs were
the lowest with the 1st and 2nd trimester screening policy, while the no screening policy
had the highest total costs.
Table 8. Direct costs of each screening strategy, using baseline estimates (per 100,000
patients)
No
screening

Routine 1st trimester
screening

1st and 2nd trimester
screening

0

1,242,000

2,465,000

Costs of acute care
(pyelonephritis and ARDS) ($)

22,303,000

13,334,000

6,777,000

Total expected costs ($)

22,303,000

14,576,000

9,242,000

Costs of ASB screening and
treatment ($)

Table 9 demonstrates the results of the base-case analysis comparing the no screening
strategy to first trimester and first/second trimester urine culture screening strategies.
A hypothetical cohort of 100,000 pregnant women was used to illustrate the differences
in the results more clearly. With a policy of no screening, our model predicts a rate of
pyelonephritis of 26.7 per 1000 pregnancies. With no screening, there are significantly
more cases than predicted for the single urine culture strategy (16 per 1000
pregnancies) and the two urine culture strategy (8.1 per 1000 pregnancies). Reductions
in the incidence of more significant maternal outcomes such as ARDS are also noted
with a two urine culture strategy from 133 expected cases (no screening) to 41 expected
cases (two culture strategy).
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Although costs associated with increased screening for and treatment of asymptomatic
bacteriuria result in greater initial expense with the one and two urine culture strategies
compared to no-screening, these costs are small compared to the expected savings from
avoiding in-patient care for pyelonephritis and acute respiratory distress syndrome.
Table 9. Results summary for baseline estimates (per 100,000 patients)

No screening
2,669

Routine 1st
trimester
screening
1,596

1st and 2nd
trimester
screening
811

---

1,073

1,858

133

80

41

---

53

92

$22,303,000

$14,576,000

$9,242,000

Cost savings
(vs no screening)

---

$7,727,000

$13,061,000

Incremental cost savings
(vs 1st TM screening)

---

---

$5,334,000

Variable
Expected cases of
pyelonephritis (#)
Pyelonephritis prevented (#)
(vs. no screening)
Expected cases of ARDS (#)
ARDS prevented (#)
(vs no screening)
Expected costs of strategy

Unlike most additional screening tests which introduce increased expenses in order to
improve health, an additional urine culture is predicted to not only reduce the risk of
adverse maternal outcomes (by preventing pyelonephritis and ARDS), but is also
expected to bring substantial cost savings. As such, there is no true cost per
pyelonephritis prevented. Rather costs saved are in addition to cases of pyelonephritis
prevented. This is the case when routine first trimester screening is compared to a no-
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screening strategy. The improved health states and costs are magnified with a repeat
urine culture in the 2nd trimester (i.e. 18-22 weeks GA).
A series of univariate sensitivity analyses were performed, changing the baseline
probabilities and cost estimates across their plausible ranges. The repeat screening
strategy remained the dominant strategy over both single screening and no screening
strategies, except with regard to two variables. The cost-effectiveness of repeat
screening was affected by the risk of progression to acute pyelonephritis among
untreated bacteriuric women. When the risk of pyelonephritis was less than 4% (base
case 21%), the two urine culture strategy no longer dominated the other two strategies
and became more expensive than the single urine culture strategy. However, at this
threshold, the two urine culture strategy continued to be the strategy that maximized
maternal outcomes. In fact, when the probability of pyelonephritis in the untreated
woman was reduced to 2.5% the cost to prevent one case of pyelonephritis with this
strategy (compared to one urine culture strategy) would be $4,664. In addition, when
the cost of a urine culture exceeded $65, screening in the first and second trimester was
no longer the dominant strategy. The single screening strategy became the cheapest
policy when the cost of the urine culture was between $65 and $89, while the no
screening strategy had the lowest overall cost when the urine culture exceeded $89. If a
urine culture costs $100, the cost to prevent one case of pyelonephritis with this 2
culture strategy (compared to one urine culture strategy) would be $4,423.
Nonetheless, for any urine culture cost, the 1st and 2nd screening strategy remained the
most cost-effective strategy and maximized healthy outcomes for pregnant women.
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Discussion
Throughout the literature, it is reported that the incidence rate of ASB after an initial
negative urine culture did not exceed 1-2%; however, the incidence of pyelonephritis
amongst this same cohort of women was cited to be also between 1-2%. Closer
analysis of these statistics raised the possibility that more women were becoming
bacteriuric than the literature from the 1950s and 1960s suggested. Amongst our
prospective cohort of women seeking prenatal care, a greater proportion of women
developed ASB after a negative first urine culture in comparison to reports in the
literature. The overall calculated incidence rate of ASB through 28 weeks GA amongst
such women was 4.3% (95% CI 1.75 – 8.96%). This incidence rate may be
underestimated as positive cultures with less than 100,000 CFU/mL were excluded from
ASB calculations. Notably, women with known risk factors (i.e., diabetes mellitus, sickle
cell trait, and immunosuppression) for ASB did not develop ASB at significantly
increased rates in comparison to women without such risk factors – a finding that
suggests that targeted screening of women with identifiable risk factors will not lead to
increased detection of ASB.
Although our cohort did not have excess risk factors for ASB, its other characteristics,
namely multiparity and low socio-economic status, have been associated with increased
ASB prevalence. Despite the fact that the population prospectively followed was
predicted to have a greater risk of ASB, the rate of ASB on initial culture was consistent
with previously reported rates. The prevalence rate of ASB at initial culture, adjusted
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for the use of a single diagnostic culture, was 7.7%. This prevalence falls within the
range of ASB prevalence reported across various obstetric populations.
Like previous studies, we found E coli to be the predominant pathogen responsible for
ASB. Interestingly, gram-positive organisms comprised a larger percentage of
bacteriuria cases than prior studies have indicated. Hill et al, in a recent prospective
longitudinal study of acute pyelonephritis, found that the frequency of gram-positive
organisms doubled by the third trimester and such pathogens accounted for an
increasing proportion of cases of acute pyelonephritis.(19) As a result of screening
from the first prenatal visit until early in the third trimester, our data may have captured
this shift in microbiology from predominantly gram-negative organisms to more grampositive organisms. It is possible that a single screening in early pregnancy may miss
the detection of gram-positive organisms that appear later in gestation.
Interestingly, the development of ASB, after a negative culture, occurred most often in
the window between 18 and 22 weeks gestational age. This peak in ASB incidence,
albeit not statistically significant, was seen also amongst all cases of ASB and amongst
any positive culture. This increase in incidence in the 18 to 22 week GA interval has
biological plausibility. It occurs as the enlarging uterus extends beyond the pelvis,
compressing the ureters, and as the placenta continues its increasing production of
progesterone, physiologic changes that may predispose women to greater urinary stasis
and bacterial proliferation. Moreover, as women engage in sexual activity throughout
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pregnancy, bacteria will be introduced in the sterile urinary tract and changes of
pregnancy may contribute to enhanced bacterial growth.
As most cases of pyelonephritis occur in the second and third trimester, the goal of any
screening program would be to identify cases of ASB before their progression to
symptomatic infection; the mid-trimester peak in our study suggests a logical time for a
second screening urine culture in pregnancy. Larger studies will be required to
determine if this peak in incidence at 18-22 weeks will be replicated in other
populations. In a cohort of 1050 women, McIsaac and colleagues (2005) reported that a
single culture early in pregnancy failed to identify more than half of the cases of ASB,
concluding that additional cultures are required; however, they made no assessment of
the impact of increased ASB detection on incidence of acute pyelonephritis in
pregnancy. Larger randomized controlled trials would help to resolve the question as to
whether repeat screening decreases the incidence of pyelonephritis as the true
objective is to prevent additional cases of pyelonephritis that would be missed by a
single culture strategy.
Our study did not have sufficient power to compare the incidence of pyelonephritis
between a repeat screening strategy and a single culture strategy. Nonetheless, the
incidence rate of pyelonephritis in our study was 1.5%, consistent with the published
incidence rate of pyelonephritis in pregnancy of 1-2%.(19, 21) Interestingly, there was
only one case of acute pyelonephritis amongst all women with ASB; this woman was
non-adherent to her antibiotic regimen in addition to being immunosuppressed. There
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were no significant associations between bacteriuria and low birthweight or preterm
birth,
Like Rouse et al, we found that use of a single urine culture for ASB screening in
pregnancy was cost-saving in comparison to no screening. Furthermore, our study
demonstrates that repeat ASB screening and treatment is also cost-effective in
comparison to a no screening strategy and to the standard one urine culture strategy,
and provides a strong case for the multiple screening strategy. It should be noted that
our cost estimates most likely represented an underestimation of the total costs as we
only considered direct hospital costs. The sensitivity analyses revealed the dominance
of repeat screening over the alternative strategies for almost every plausible probability
value and cost estimate. These results can be attributed to the relatively low cost of
urine cultures in pregnancy compared to high costs of inpatient management of acute
pyelonephritis in pregnancy. Some researchers have suggested that uncomplicated
pyelonephritis can be treated effectively and safely on an outpatient basis; however, the
relatively high rate of complications arising in pregnant women with pyelonephritis
(respiratory insufficiency, need for intensive care unit admission, and septicemia) will
limit the widespread implementation of outpatient management and maintain the
relatively high costs of acute antepartum pyelonephritis.(58)
The variables that most affected the cost-effectiveness outcome are the cost of urine
culture and the risk of progression of untreated ASB to acute pyelonephritis.
Understandably when the screening tool, namely the urine culture, becomes too
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expensive, then screening, and in this case repeat screening, is no longer cost-saving.
Likewise when the risk of pyelonephritis among untreated bacteriuric women is lower,
the benefit of ASB screening becomes less. Nonetheless, the two urine culture strategy
continued to be the strategy that maximized maternal outcomes across all costs and
probability estimates.
We recognize that the multiple screening strategy has its drawbacks. Obtaining urine
for culture in all prenatal patients can add additional work to busy obstetric practices.
Providers will be required to follow-up cultures results, prescribe appropriate
antibiotics, and perform repeat cultures as tests of cure. Importantly, there is concern
that inappropriate antibiotic use will lead to increasing antibiotic resistance. There are
no current treatment recommendations for cultures with less that 100,000 CFU/mL as
there are unclear implications of lower colony counts in pregnancy. In the absence of
guidelines around lower colony counts, we found that physicians and midwives were
using antimicrobial agents to treat urine cultures that did not meet the criteria for ASB
due to concerns about the risks of untreated bacteriuria in pregnancy. In our study, a
high rate of antibiotic resistance was observed among E coli and other pathogens, a
finding that is consistent with reports in the literature.(35) Moreover, antibiotics have
adverse effects including gastro-intestinal upset, Clostridium difficile infection, allergic
reactions, and the development of symptomatic yeast infections. Yet despite these
concerns regarding antibiotic use, our analysis strongly demonstrates that repeat
screening offers the dual benefit of preventing additional cases of pyelonephritis and
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decreasing overall health care costs. Any implementation of a multiple ASB screening
strategy would require guidelines and provider education about appropriate antibiotic
use in the care of pregnant women.
There are several limitations to our study. Our study cohort was mostly multiparous
women of color with lower than average socioeconomic status, a population that may
not reflect a typical obstetric practice. The estimate of ASB prevalence on repeat
culture after an initial negative culture used in the cost analysis was derived from this
cohort, and thus may not be universally applicable to antepartum populations.
Moreover, the peak incidence of ASB after an initial negative culture was not statistically
different than the other four week gestational age windows studied, and a larger sample
size may be needed in order to detect differences in ASB incidence rates in four week
intervals and to determine the most optimal time to perform a second urine culture. In
addition, the frequent treatment of urine cultures that did not meet criteria for ASB
most likely led to an underestimation of the true rate of ASB on repeat culture.
Nonetheless, this study is one of the few to evaluate repeat ASB screening and
treatment in the prevention of pyelonephritis in pregnancy. The strength of the analysis
lies in the persistence of the cost-benefit findings of repeat screening over a wide range
of probabilities and costs. Before implementation of a repeat screening policy, larger
studies will be needed to determine if screening in both first and second trimesters can
indeed reduce the incidence of acute antepartum pyelonephritis. If multiple cultures are
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shown to decrease this incidence rate, our results offer strong evidence for the benefits
of routine ASB screening in the first and second trimesters.
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APPENDIX

Abbreviation Key
PROBABILITIES
pARDS

probability of ARDS

pASB1TM

probability of ASB in first trimester

pASB2TM

probability of ASB in second trimester

pASBpersistent

probability of persistent ASB

pASBrecurrence

probability of ASB recurrence after treatment

pPyelo1NegCx

probability of pyelonephritis with 1 negative screening culture

pPyelo2NegCx

probability of pyelonephritis with 2 negative screening cultures

pPyeloASBRx

probability of pyelonephritis after ASB treatment

pPyeloNoRx

probability of pyelonephritis with untreated ASB

pRx

probability of treatment

pRxNoScreen

probability of treatment with no screening

COSTS
cARDS

cost of inpatient ARDS management

cASBTreatment

cost of ASB treatment

cNoScreen

cost of no screening

cPyelo

cost of inpatient management of acute pyelonephritis

cSuppression

cost of antibiotic suppression

cUCx

cost of urine culture

UTILITIES
uARDS

utility of ARDS

uHealthy

utility of "healthy"

uPyelo

utility of pyelonephritis
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APPENDIX A. Decision analysis tree for policy of no screening
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APPENDIX B. Decision analysis tree for policy of first trimester screening (1 culture strategy)
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Appendix C. Decision analysis figure for policy of first and second trimester screening (2 culture
strategy)
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